Skip to main
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV is positioned for potential stock price appreciation given the possibility of advancing its pipeline products into clinical trials more swiftly than expected, which could yield proof of concept data in humans. The company's Axiomer RNA base-editing platform is viewed as a promising asset, with anticipation surrounding upcoming clinical data from the first-in-human study of its lead candidate. Additionally, the management's assertion that the current cash position is adequate to sustain operations until mid-2027 provides financial stability, bolstering investor confidence in the company's future endeavors.

Bears say

ProQR Therapeutics NV reported a net loss of -€12.2 million for the quarter, significantly widening from a loss of -€2.7 million in the same period in the previous year, indicating worsening financial performance. The company's reliance on the outcomes of ongoing Phase Ib/II/III studies presents inherent risks, as negative results could exert downward pressure on its stock value. Additionally, advancements in competitor treatment methods pose a threat to the company’s existing therapies, potentially rendering them non-competitive or obsolete.

ProQR Therapeutics (PRQR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 7 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.